Protalix BioTherapeutics Inc. (DE) (PLX) director Melincoff received 7,500 shares

Insider transactions reported

Gwen A Melincoff (director at Protalix BioTherapeutics Inc. (DE), PLX) reported that they received 7,500 shares on Sep 3, 2025. After these transactions the filing shows 7,500 shares held indirectly (By Trust).

Reporting person

Melincoff Gwen A

Options and other derivatives

Holdings before and after

• Common Stock: 0 to 7,500 indirect, By Trust
• Stock Options (Right to Buy): 0 to 15,000 direct

Footnotes from the filing

1. 1. Represents restricted shares of common stock awarded to the Reporting Person under the Amended and Restated Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended (the Plan ). The restricted shares vest in 12 equal quarterly installments commencing upon the date of grant.
2. 2. To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued under the Plan must be registered in the name of a trustee.
3. 3. The shares of common stock underlying the stock options shall vest in 12 equal quarterly installments commencing upon the date of grant.
4. 4. Does not include (i) options to purchase 40,000 shares of common stock at an exercise price equal to $3.55 per share that expire on January 20, 2030, (ii) options to purchase 50,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 7, 2032 and (iii) options to purchase 61,676 shares of common stock at an exercise price equal to $1.66 per share that expire on September 29, 2033.

Transaction codes in this filing

Grant or award:

Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.

FAQ